Stocks of Akebia Therapeutics Inc (NASDAQ:AKBA) traded higher last session on Wall Street, up 7.59% to $3.97.
AKBA stock price is now 63.71% away from the 50-day moving average and 103.45% away from the 200-day moving average. The market capitalization of the company currently stands at $1.04B.
On April 28, 2025, Leerink Partners recently initiated its ‘Outperform’ rating on the stock quoting a target price of $7, while ‘Jefferies’ rates the stock as ‘Buy’
In other news, Malabre Richard C, SVP, Chief Accounting Officer sold 13,334 shares of the company’s stock on Jun 04 ’25. The stock was sold for $47,069 at an average price of $3.53. Upon completion of the transaction, the SVP, Chief Accounting Officer now directly owns 266,914 shares in the company, valued at $1.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, CEO and President Butler John P. sold 46,409 shares of the business’s stock. A total of $84,928 was realized by selling the stock at an average price of $1.83. This leaves the insider owning 2,557,921 shares of the company worth $10.15 million. A total of 4.10% of the company’s stock is owned by insiders.
During the past 12 months, Akebia Therapeutics Inc has had a low of $0.80 and a high of $3.73. As of last week, the company has a debt-to-equity ratio of 8.39, a current ratio of 2.23, and a quick ratio of 2.02.
The company reported revenue of $57.34 million for the quarter, compared to $32.61 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 75.84 percent.
